Printer Friendly

Articles from M2 Pharma (August 31, 2016)

1-18 out of 18 article(s)
Title Author Type Words
Amgen reveals positive top line results in phase three study of Prolia. Clinical report 191
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. 252
Atossa Genetics to issue common stock in public offering. 124
Bio2 Medical Raises USD 3m from Venture Debt Financing. 156
Biocept partners with Teneovita Medical to market and distribute its liquid biopsy testing platform in Canada. 211
Biocom names new directors. 203
BioInvent International signs extended contract for manufacturing services with existing customer. 140
Bluegrass Vascular Secures CE Mark Approval for Surfacer Inside-Out Access Catheter System. 325
Brazil's ANVISA Clears Apira Science Wearable Laser Device. 116
Innovus Pharmaceuticals unveils brain health supplement RecalMax in the US market. 270
OPKO Health acquires Transition Therapeutics. 183
Orexigen Therapeutics to commercialise Contrave in Canada in the obesity medication market through Valeant. 260
PharmCo awarded non-resident license in Georgia. 111
Pliant Therapeutics elects Suzanne Bruhn, PhD to board. 119
Qualcomm, Boehringer Ingelheim Pharmaceuticals Work to Add New Digital Technology to Respimat inhaler. 259
Rigel Pharmaceuticals achieves primary endpoint in first double-blind study of fostamatinib for treating chronic ITP patients. Clinical report 345
Tizona Therapeutics names new director. 253
Tonix receives final meeting minutes from End-of-Phase 2/Pre-Phase 3 meeting for TNX-102 SL from US FDA. 232

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters